Sexual function and health status in adult patients with Congenital Adrenal Hyperplasia.

Autor: Dobrowolska-Glazar B; Department of Pediatric Urology, Jagiellonian University Medical College, Kraków, Poland. Electronic address: Barbara.Dobrowolska-Glazar@uj.edu.pl., Honkisz I; Department of Pediatric Urology, Jagiellonian University Medical College, Kraków, Poland., Sulislawski J; Department of Pediatric Urology, Jagiellonian University Medical College, Kraków, Poland., Tyrawa K; Department of Pediatric Endocrynology, Jagiellonian University Medical College, Kraków, Poland., Wolnicki M; Department of Pediatric Urology, Jagiellonian University Medical College, Kraków, Poland., Chrzan R; Department of Pediatric Urology, Jagiellonian University Medical College, Kraków, Poland.
Jazyk: angličtina
Zdroj: Journal of pediatric urology [J Pediatr Urol] 2020 Aug; Vol. 16 (4), pp. 464.e1-464.e6. Date of Electronic Publication: 2020 May 31.
DOI: 10.1016/j.jpurol.2020.05.162
Abstrakt: Introduction: Congenital Adrenal Hyperplasia (CAH) is the most common reason for undifferentiated genital appearance in new-borns. Psychosexual outcome in women with CAH has been rarely evaluated, but it seems to be one of the most important factors determining the indications for the surgical treatment of CAH.
Objective: This is to assess sexual function and the health status (HS) in adult females with CAH who had feminizing genitoplasty in childhood.
Material and Method: The protocol was approved by the Ethical Committee, and the hospital database was searched for patients with CAH who had genitoplasty between 1975 and 2000. 57 adult patients were identified, and 9 (18%) patients agreed to participate in the study. Mean age at operation was 5.4 years, and mean follow-up duration was 10.9 years. The Female Sexual Function Index (FSFI) was used to evaluate sexual function, and the 36-item Short Form Health Survey (SF-36) was used to evaluate their health status (HS). A FSFI score < 26,55 was classified as Female Sexual Dysfunction (FSD). The control group consisted of 10 adult female volunteers of comparable age, without any oncological or chronic diseases. Fisher's exact test was used for statistical analysis.
Results: All patients in the CAH group had female gender identity. One was homosexual, and one reported not having any sexual activity. In the control group, all patients had female gender identity. All were heterosexual and one reported not having any sexual activity. The sexual function in five domains and total score were similar in both groups. More pain was reported in the CAH group as compared with the control group, and it was statistically significant. In the CAH group, 5/9 patients had FSD. In the control group, 4/10 patients had FSD. The difference was statistically insignificant (p = 0.66). Mean SF-36 score in the CAH group was 47.1 points, while it was 46.7 points in the control group. The testosterone level in all CAH patients was within the normal range (0.13-1.1 ng/ml). The 17-OH progesterone level was above normal range in 5/9 (55.6%) patients with CAH. All women in the CAH group were hormonally treated. In the control group, all patients had a normal testosterone level (0.15-0.68 ng/ml); the 17-OH progesterone level was in normal range in this group.
Discussion: We compared our results with the literature data, which used the same questionnaires as in our study.
Conclusions: Health status and sexual function in the traceable CAH patients didn't differ from the control group.
Competing Interests: Conflicts of interest We have no conflicts of interest to disclose.
(Copyright © 2020 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: